Single registrationBuy Now
The emerging medical foods market in the United States is $1.3 billion annually with strong growth potential. As a distinct, FDA-regulated category, medical foods are gaining more widespread acceptance. However, they remain poorly understood by patients, pharmacists and physicians. This webinar will describe the regulatory pathway for approval, the definition of a medical food, examples of medical foods, and product development opportunities.
Why Should You Attend:
As a distinct, FDA-regulated category, medical foods represent a substantial nutritional market opportunity. However, they remain poorly understood by patients, pharmacists and physicians. The development and sales of medical foods involve fewer regulatory requirements than those needed for drug development and approval.
Unlike foods for special dietary purposes (such as a food allergy or difficulty in swallowing, or nutrients intended to meet ordinary nutritional requirements) the FDA views medical foods as an integral component of the patient's clinical management.
Medical foods are specifically formulated and processed for a patient who is seriously ill or requires use of the product as a major component of a disease or condition’s “specific dietary management.” Medical foods must be labelled for the “dietary management of a specific disease” rather than for a treatment of a disease or medical condition. A distinctive nutritional requirement based on recognized scientific principles must be established. Also, a patient must be receiving active or ongoing medical supervision and must be provided instructions on the use of the medical food.
FDA (1996) advised that the term "specific dietary management” means that medical foods can be an integral part of the clinical treatment of patients to help "ameliorate clinical manifestations of the disease," "favorably influence the disease process," and "positively influence morbidity and mortality (patient outcomes).” Thus, any pharmaceutical/nutritional company that is interested in developing products for medical conditions should be aware of the product opportunities for medical foods.
Areas Covered in the Webinar:
Who Will Benefit:
Physical CD-DVD of recorded session will be despatched after 72 hrs on completion of payment
Alan S. Ryan, PhD is a recognized scientist with over 150 articles and 40 years of experience in preclinical and clinical research, including protocol development, report writing, publications, and FDA submissions. Dr. Ryan has published extensively on infant feeding practices, breastfeeding trends, childhood growth and development, body composition, cardiovascular disease, and omega-3 fatty acids. He supervised over 50 clinical trials involving the development of new infant formulas and medical foods. He managed the successful submission of two new drug applications (NDAs): one for Lovaza® (formerly Omacor®), an omega-3 fatty acid drug for the treatment of hypertriglyceridemia, and the second for NeoProfen®, an "orphan" IV drug for the treatment of patent ductus arteriosus in premature infants. As a consultant, Dr. Ryan has prepared protocols for Phase II and III trials, articles for publication, and regulatory materials for IRB approval including Type B meetings. He wrote protocols, articles and final reports for medical food, drugs, and dietary supplements for the treatment and management of cardiovascular disease, pain, CNS disorders, cognitive function, kidney stones, and drug abuse.